NIH initiative to 'rigorously evaluate' benefits, harms of e

NIH initiative to 'rigorously evaluate' benefits, harms of evolving cancer screening technologies

The prospect of screening for multiple cancer types simultaneously through a blood draw or other simple methods has generated tremendous excitement. Multicancer detection tests — often called liquid biopsies — measure circulating tumor cells, tumor DNA or other substances in the blood, urine or other body fluids that can identify the presence of cancer.

Related Keywords

Virginia , United States , Colorado , North Carolina , University Of North Carolina , India , Virginia Commonwealth University , America , Virginians , American , Henry Ford , S Patrick Nana Sinkam , Christine Neslund Dudas , Alex Krist , Daniels Reuland , Mindy Valcarcel , Lori Minasian , Jeffreyk Lee , Byjennifer Byrne , Massey Comprehensive Cancer Center , Clinical Laboratory Improvement Amendments , University Of Colorado Cancer Center , Department Of Defense Uniformed Services University , Us Preventive Services Task , Lineberger Comprehensive Cancer Center , University Of North Carolina At Chapel Hill , Fred Hutch Cancer Center , Department Of Defense , Kaiser Permanente School Of Medicine , Henry Ford Health , Kaiser Permanente Northern California Division Of Research , Alliance For Oncology Clinical Trials , Theranos Inc , Sentara Health , Washington University School Of Medicine , Cancer Screening Research Network , Department Of Veterans Affairs , National Lung Screening Trial , Michigan State University Health Sciences , Services Task Force , Cancer Moonshot , Hutch Cancer Center , Ford Health , Permanente Northern California , Kaiser Permanente Southern California , Kaiser Permanente School , Stephenson Cancer Center , Oklahoma Health Sciences , Colorado Cancer Center , Comprehensive Cancer Center , Chapel Hill , Commonwealth University , University School , Veterans Affairs , Defense Uniformed Services University , Kaiser Permanente Northern California Division , Silicon Valley , Oncology Clinical Trials , African American , Patrick Nana Sinkam ,

© 2024 Vimarsana